SYNI
Live / Registered — Registered (as of 14 Oct 2025)
What this means for you
Registered since 14 Oct 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79414045
- Registration number
- 7979910
- Mark type
- Stylized text
- Filed
- 29 Nov 2024
- Published for opposition
- 26 Aug 2025
- Registered
- 14 Oct 2025
- Attorney of record
- Stephen Drysdale
Goods and services
- Class 005 — Pharmaceuticals: Food supplements, namely, anti-oxidants; capsules sold empty for pharmaceutical purposes; capsules sold empty for veterinary pharmaceutical preparations; chemical preparations for pharmaceutical use to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; collagen based medicated supplements for use as nutritional supplements; decoctions for pharmaceutical purposes to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; antioxidants in the nature of dietary supplements; dietary protein supplements; dietary supplements; dietary supplements for animals; dietary supplements with a cosmetic effect; effervescent pharmaceutical preparations to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; food supplements for medical purposes to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; herbal dietary supplements; dietary nutritional supplements; nutritional supplements; plant extracts, other than essential oils, being dietary supplements; medicated lozenges for pharmaceutical purposes; skin lotions for pharmaceutical purposes; pharmaceutical preparations to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; pharmaceutical preparations containing vitamins to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; pharmaceutical preparations for health care to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; pharmaceutical preparations for human use to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; pharmaceutical preparations for oral use to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; pharmaceutical preparations for skin care; pharmaceutical preparations for veterinary use to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; chemical products in the nature of chemical preparations for pharmaceutical use to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; natural pharmaceutical products to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; pharmaceutical products to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; tablets being pharmaceuticals to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; food supplements for animals in the nature of vitamins; vitamin supplements; dietary food supplements; nutritional drinks being dietary food supplements; food supplements in the nature of dietary supplements.
Owner
- BIOGENCY PTY LTD, AU
- BIOGENCY PTY LTD, AU
- BIOGENCY PTY LTD, AU
Prosecution history
- 14 Jan 2026 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 14 Oct 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 14 Oct 2025 — REGISTERED-PRINCIPAL REGISTER
- 26 Aug 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Aug 2025 — PUBLISHED FOR OPPOSITION
- 20 Aug 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 18 Jul 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 14 Jul 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 14 Jul 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 14 Jul 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 05 Jul 2025 — REFUSAL PROCESSED BY IB
- 24 Jun 2025 — ASSIGNED TO LIE
- 14 Jun 2025 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 14 Jun 2025 — REFUSAL PROCESSED BY MPU
- 11 Apr 2025 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW